Journal of VirologicalMethods, Elsevier Biomedical
AUTOMATED ANTIVIRAL
ENZYME-LINKED ANTIBODIES:
NEURATH’
A. ROBERT
4 (1982)
303
291-
291
Press
FLUORESCENCE
IMMUNOASSAYS
FOR
A TEST FOR ANTI-HBs
, NATHAN
STRICK’
and SETH GOODMAN*
’ The Lindsley F. Kimball Research Institute of the New York Blood Center, New York, NY 10021; and ’ Gilson MedicaI Electronics, (Accepted
18 February
A solid-phase antigen
linked
The
test samples antibodies
fluorescence
subsequently
was automated.
of a commercial
U.S.A.
immunoassay
coli p-galactosidase
is described.
were adsorbed were
fluorescence
to Escherichia
umbelliferyl-p-D-galactopyranoside) from
WI 53562,
1982)
enzyme-linked
covalently
Inc., Middleton,
Antibodies
to wells of 96-well detected
The sensitivity
using
(ELFA)
for
antiviral
and a fluorogenic to hepatitis
aminopolystyrene enzyme-conjugated
antibodies
substrate
B surface
antigen
plates precoated HBsAg.
of the test was approximately
using
(4-methyl(HBsAg)
with HBsAg.
The measurement
50 times higher
of
than that
radioimmunoassay.
enzyme-linked
fluorescence
immunoassay
hepatitis
B surface
antigen
surface
antibody
INTRODUCTION
Enzyme-linked fluorescence immunoassays (ELFA) combine the advantages of enzyme-labeled immunoassays (ELISA), i.e. stability of reagents and lack of potential health
hazards,
and of radioimmunoassays,
i.e. high sensitivity
(Ishikawa
and Kato,
1978; Yolken and Stopa, 1979; Neurath and Strick, 1981). Enzyme-labeled antibodies were utilized in these ELFA tests. The usefulness of ELFA for diagnostic purposes would be further extended by the availability of enzyme-labeled antigens and by the automation of fluorescence measurements. In accordance with such aims, we developed an automated ELFA for antibodies to hepatitis B surface antigen (HBsAg) using HBsAg conjugated with /I-galactosidase. MATERIALS
AND METHODS
Covalent linking of HBsAg to polystyrene
microtiter plates
Wells of 96-well polystyrene tissue culture plates (cat. No. 3042, Falcon Products, Oxnard, CA) were nitrated and subsequently reduced with dithionite as described before (Neurath and Strick, 1981). Wells of the resulting aminopolystyrene plates were filled 0166-0934/82/0000-0000/$02.75
@ 1982 Elsevier Biomedical
Press
with 200 ~1 of a solution containing HBsAg subtype ad (100 pg/ml), oxidized as described below, and incubated overnight at 4°C. The unattached HBsAg was removed by aspiration. The wells were filled with a solution of bovine hemoglobin (10 mg/ml in 0.14 M NaCl, 0.01 M Tris, 0.02% NaNa, pH 7.2 (TS)) and the plates were incubated for 4 h at 4°C. After removal of hemoglobin
the plates were washed with TS and stored wet at
4°C. HBsAg for coating of the plates was pretreated with ditions: HBsAg (500 I.cg/ml in 0.2 M sodium acetate, pH concentration 100 mM) for 30 min at 0°C dialyzed for phate, pH 6, and finally diluted 5-fold in 0.05 M sodium
NaI04 under the following con6) was treated with NaI04 (final 2 h against 0.01 M sodium phosphosphate, pH 8.5.
Conjugation of HBsAg with @-galactosidase
Two mg of HBsAg subtype ad in ~1 ml of 0.1 M sodium phosphate-O.1 M NaCl, pH 7.5 (PBS) were mixed with 10 ~1 of a solution ofN-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (10 mg/ml in ethanol; obtained either from Pharmacia Fine Chemicals AB, Uppsala, Sweden, or from Pierce Chemical Co ., Rockford, IL). After 30 min at room temperature, the mixture was chromatographed on a 0.7 X 20 cm column of Sephadex G-25 in 0.1 M acetate-O.1 M NaCl, pH 4.5. Fractions containing protein were pooled and solid dithiothreitol was added (7.7 mg/ml). After 20 min at room temperature, the mixture was chromatographed on a 0.7 X 20 cm column of Sephadex G-25 in PBS. Fractions containing the major portion of protein were pooled and mixed with 1 mg of E. coli fl-galactosidase (600 units/mg; cat. No. 567779; Boehringer Mannheim Biochemicals, Indianapolis, IN) for 2.5 h at 20°C followed by 16 h at 4°C. The volume of the mixture was reduced to l-2 ml and submitted to rate zonal centrifugation (16 h at 25,000 r.p.m., Spinco rotor SW27) in a 10-35s (v/v) glycerol gradient in TS. Fractions of 2 ml were collected from the bottom of the gradients. Appropriate aliquots of the fractions were tested for HBsAg (1 ~1) by radioimmunoassay (RIA) and for P-galactosidase activity (0.075 ~1). The percentage of HBsAg recovered per fraction was calculated from a calibration curve relating radioactive counts measured in RIA to serial 5-fold dilutions of HBsAg-enzyme conjugate prior to centrifugation. Fractions containing the highest concentration of HBsAg (fractions 5-10, Fig. 1) were pooled and stored at 4°C. One ~1 aliquots of this pool were used per ELFA test for anti-HBs. Performance
of ELFA
Samples (200 ~1) containing appropriate dilutions of anti-HBs positive serum in a solution containing bovine serum albumin (50 mg/ml) in TS (BSA-TS) were added to wells of microtiter plates precoated with HBsAg. BSA-TS was used for control blanks which were processed in the same way as serum specimens. For routine screening of human sera, specimens including negative control sera were diluted lo-fold in BSA-TS. After standing overnight at room temperature, the samples were removed by suction and
299
the plates were washed with TS. 200 ~1 of the HBsAg-/3-galactosidase conjugate diluted in BSA-TS were added per well. After 4 h at room temperature, the plates were washed with TS, 300 ~1 of the substrate solution (5 X lo-’ M 4-methylumbelliferyl-~-D-galactopyranoside in 0.01 M phosphate, pH 7.0; Sigma Chemical Co., St. Louis, MO) were added and 4-methylumbelliferone released after 30 min at 37°C was determined as described before (Neurath and Strick, 1981).
fluorometrically
Fluorescence measurements Fluorescence was measured against control blanks (= BSA-TS) in the Spectra/glo fluorometer (Gilson Medical Electronics, Inc., Middleton, WI, cat. No. 041001) equipped with filters used for determination of o-phtalaldehyde. The fluorescence was determined from the following formula: fluorescence
= 100 X
fluorometer fluorometer
printout sensitivity
range
Specimens were considered anti-HBs positive if the fluorescence than that corresponding to normal human sera. Automated
was > 2.1-fold
higher
jluorescence measurements
The system for automated fluorescence measurements from 96-well microtiter plates consists of an automatic sampler (Model 212 liquid handler, Gilson Medical Electronics, cat. No. 23101 l), a fluorometer, a peristaltic transfer pump (Gilson Model 311, cat. No. 24101 l), and a data logger (Gilson prototype). Liquids flow in the system from the probe on the sampler, through the fluorometer, peristaltic pump, and out to waste. The sampler aspirates sample from the appropriate well into the Teflon line. It introduces air bubbles before and after the sample to prevent mixing with the rinse liquid. Next, the sampler aspirates sufficient
rinse to move the sample into the fluorometer
logger then prints out sample number the next well and the whole procedure
flow cell. The data
and fluorescence. The sampler then advances to is repeated until samples from all wells are with-
drawn. The volumes of sample, air bubbles, and rinse are all programmable by controlling the amount of time the pump is on during each phase of the cycle. The pump is a special design that runs at a single constant speed and starts and stops very rapidly so that it may be turned on for very short times reproducibly. About 75 ~1 of sample is used to fill the 45 1.11fluorometer flowcell (cat. No. 04047001) so there is sufficient sample left in the well to read it several times if desired. With a continuous flow system such as this, a major concern is sample dilution and carryover. Several steps are taken to minimize these problems. 1. All tubing leading to the flowcell is Teflon which is non-wetting and reduces mixing of flowing liquids. 2. All tubing joints are of the zero dead volume type to avoid mixing. 3. The sample is separated
300
from the preceding and following rinse liquid by air bubles to avoid sample dilution. Because of the flow cell and detector design, bubbles pass through easily and it is not necessary to remove them as is often done. 4. The probe dips into a trough to aspirate rinse liquid during the rinse phase of the cycle. Provision is made for a flowing rinse to prevent accumulation of sample components in the rinse liquid. The complete cycle takes about 23 s per well, or 37 min for the 96-well plate. Other methods HBsAg was purified as described previously {Neurath et al., 1978). Commercial test kits (AUSRIA II and AUSAB, Abbott Laboratories, North Chicago, 11)were used for RIA of HBsAg and anti-HBs, respectively. RESULTS
AND DIS~~JSSION
Covalent linking of HBsAg to aminopolystyrene plates The advantages for antigen immunoassays of covalently linking antibodies to the solid phase have been described (Herrmann et al., 1979; Neurath and Strick, 1981). We used ~utaraldehyde-activated a~nopolystyrene to bind immunoglobu~s to the solid phase. Preliminary experiments (own unpublished data) revealed that the antibody binding capacity of HBsAg is diminshed as a result of reaction with glutaraldehyde. Therefore, other methods of linking HBsAg to polystyrene microtiter plates had to be considered. We chose to introduce aldehyde groups, expected to react directly with polyaminostyrene, into the saccharide moiety of HBsAg by periodate oxidation of the terminal sialic acid residues (Van Lenten and Ashwell, 1971; Neurath et al., 1975). AUSRKA tests on serial dilutions (in normal human serum) of HBsAg before and after treatment with NaI04 revealed similar titration endpoints, although the calibration curve relating counts per minute to antigen concentration was steeper for intact HBsAg (data not shown). Approximately 80% (= 16 &well) of added oxidized HBsAg was attached to the plastic and was not eluted when the coated plates were exposed for 30 min to an alkaline (pH 10.9) solution containing 10 mg/ml of sodium dodecyl sulfate. This suggests that HRsAg was covalently linked to the solid support. Conj~~ti~n ofIi&& with ~-galaetosidase The heterobifunctional
reagent N-succinimidyl-3-(2-pyridyldithio)propionate
(SPDP)
is the cross-linking agent of choice for conjugation of antibodies with /3-galactosidase (Neurath and Strick, 1981). In considering the use of SPDP for linking of this enzyme with HBsAg, we were concerned with possible alterations of the immunological specificity of HBsAg after exposure to the reducing agent dithiothreitol (Neurath and Strick, 1980) used in the course of the preparation of the conjugate. Of additional concern
301
was the possible sterical hindrance Comparative
AUSRIA
of HBsAg antigen&
tests on serial dilutions
sites by the attached
enzyme.
of HBsAg before and after conjugation
indicated that the derivatization resulted in an acceptable 60% decrease of HBsAg titer. The HBsAg-/I-galactosidase conjugate was separated from the bulk of free enzyme by rate zonal centrifugation (Fig. 1). The activity of the conjugate did not decrease during storage at 4°C for 4 months (longer periods were not tested). The successful conjugation of HBsAg with fl-galactosidase suggests that other virus antigens, including those with disulfide bonds essential for their antigenicity, may be linked with enzymes using SPDP and that the resulting conjugates may become useful for development of ELFA or ELISA tests. EL FA tests of an ti-HBs Preliminary
tests revealed the presence
in normal human sera of a component(s)
re-
IO-
oI
I I I I I I I I 3 5 7 3 II 13 I5 17 FRACTION NUMBER
Fig. 1. Comparative in lo-
cross-linking in which ment.
results
35% (v/v) glycerol of HBsAg maximum
of rate zonal gradients
with
quantities
centrifugations
of p-galactosidase
p-galactosidase
(bottom).
(16 h at 25,000
r.p.m.,
Spinco
($0 pg; top) and of the product Arrow
of free HBsAg were recovered
indicates
the fraction
when centrifuged
rotor resulting
SW 27) from
of the gradient
in a separate
experi-
302
acting with the HBsAg-fl-galactosidase conjugate. This resulted in high levels of background fluorescence for anti-HBs-negative sera. Moreover, this fluorescence varied for different human sera. Therefore, all sera screened for anti-HBs were diluted at least lofold in BSA-TS. This resulted in a substantial decrease of fluorescence corresponding to anti-HBs-negative blanks and in increased sensitivity of anti-HBs detection (Fig. 2). Comparative ELFA and AUSAB tests on serial dilutions of the same sera indicated that the sensitivity of ELFA is about 50 times higher than that of the AUSAB test. To assess the comparative efficiency of the AUSAB and ELFA tests in screening of sera for anti-HBs, serum specimens from 100 randomly selected blood donors were analyzed by both tests. Anti-HBs was detected in five sera by the AUSAB test. The same sera (diluted lo-fold in BSA-TS) were also positive as determined by ELFA. Additional two sera were positive using the latter test. (The mean fluorescence corresponding to negative specimens was 1.5 with a variance of 1 .l; positive specimens had a fluorescence > 6.3). Addition of 50 pg of each of HBsAg subtypes ad and ay to sera which appeared anti-HBs positive by ELFA resulted in decreased fluorescence readings, thus confirming that all seven sera contained anti-HBs. As mentioned before, ELFA tests combine the advantages of ELISA and RIA tests. However, previously described ELFA tests (Ishikawa and Kato, 1978; Yolken and Stopa,
l60-
kj 120-
:
z &oo-
1
z g
ao-
3 k
60-
ot,, 10-7
10-6
DILUTION Fig. 2. Calibration
anti-HBs-positive line indicates
lo-5
curve human
background
the substrate
solution
still positive
by
normal
human
and decreased
IO-~ IO-~ IO-’
IO-~
OF ANTI-HBs
the
serum further
POSITIVE
for anti-HBs. serum
Serial 2-fold
in a solution
fluorescence
which AUSAB
SERUM
corresponding
was not incubated test
was
dilutions
reaching
to blanks.
2 X 10-5-fold. background
with a lo-fold
in TS) were tested. Fluorescence
at 37°C. The highest
was the same as that corresponding by dilution
(starting
of BSA (50 mg/ml
Fluorescence
dilution
levels at a 10e4 dilution.
of an
horizontal
was measured at which
corresponding
to 6 x 10e5 diluted
dilution)
Broken
against
this serum was to 10-l
diluted
anti-HBs-positive
serum
303
1979; Yolken fluorescence mits
rapid
et al., 1980; Neurath readings.
and Strick,
Such automation,
fluorescence
described
measurements
1981) did not utilize automation
of
for the first time in this report, per-
(?J 23 s/sample)
and eliminates
the need for
manual operations in the course of reading 96 samples corresponding to one microtiter plate. Work now in progress promises to reduce this time substantially. Our results show that ELFA tests can be automated and applied for screening of large numbers of specimens in a clinical laboratory setting. ACKNOWLEDGEMENTS
This study was supported in part by Grant C 172100 from the New York State Health Research Council. We thank Dr. L. Baker for sera containing HBsAg and anti-HBs, respectively. REFERENCES
Herrmann, Ishikawa,
J.E., R.M. Hendry E. and K. Kato,
and M.F. Collins,
1978, Stand.
1979,J.
J. Immunol.
Neurath,
A.R., N. Strick,
Neurath,
A.R. and N. Strick,
1981, J. Virol. Methods
Neurath,
A.R., N. Hashimoto
and A.M. Prince,
Neurath,
A.R., A.M. Prince and J. Giacalone,
Van Lenten,
Clin. Microbial.
8, Suppl.
10, 210
7,43.
1980, J. Med. Virol. 6,309.
L. and G. Ashwell,
YoIken,
R.H. and P.J. Stopa,
YoIken,
R.H., V.M. Torsch,
3,155.
1975, J. Gen. Virol. 27,81. 1978, Experientia
34,414.
1971, J. Biol. Chem. 246, 1889.
1979, J. Clin. Microbial. R. Berg, B.R. Murphy
10,317.
and Y.C. Lee, 1980, J. Infect.
Dis. 142,516.